title: Cytomegalovirus infection following stem cell transplantation.
authors.affiliation: Medizinische Klinik und Poliklinik, University Hospital, Tübingen, Germany. hneinsel@med.uni-tuebingen.de
authors.forename: H
authors.initials: H
authors.lastname: Einsele
authors.forename: H
authors.initials: H
authors.lastname: Hebart
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001782:Blood Donors; D000077404:Cidofovir; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy / Q000635:transmission; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006412:Hematopoietic Stem Cells / Q000821:virology; D006801:Humans; D016867:Immunocompromised Host; D016219:Immunotherapy, Adoptive; D017708:Leukocyte Transfusion; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011292:Premedication; D012307:Risk Factors; D014019:Tissue Donors; D065227:Transfusion Reaction; D017735:Virus Latency
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D015774:Ganciclovir; D000212:Acyclovir